Cargando…

Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer

BACKGROUND: (68) Ga-PSMA PET is the leading prostate cancer imaging technique, but the image quality remains noisy and could be further improved using an artificial intelligence-based denoising algorithm. To address this issue, we analyzed the overall quality of reprocessed images compared to standa...

Descripción completa

Detalles Bibliográficos
Autores principales: Margail, Charles, Merlin, Charles, Billoux, Tommy, Wallaert, Maxence, Otman, Hosameldin, Sas, Nicolas, Molnar, Ioana, Guillemin, Florent, Boyer, Louis, Guy, Laurent, Tempier, Marion, Levesque, Sophie, Revy, Alban, Cachin, Florent, Chanchou, Marion
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212905/
https://www.ncbi.nlm.nih.gov/pubmed/37231229
http://dx.doi.org/10.1186/s13550-023-00999-y
_version_ 1785047514787872768
author Margail, Charles
Merlin, Charles
Billoux, Tommy
Wallaert, Maxence
Otman, Hosameldin
Sas, Nicolas
Molnar, Ioana
Guillemin, Florent
Boyer, Louis
Guy, Laurent
Tempier, Marion
Levesque, Sophie
Revy, Alban
Cachin, Florent
Chanchou, Marion
author_facet Margail, Charles
Merlin, Charles
Billoux, Tommy
Wallaert, Maxence
Otman, Hosameldin
Sas, Nicolas
Molnar, Ioana
Guillemin, Florent
Boyer, Louis
Guy, Laurent
Tempier, Marion
Levesque, Sophie
Revy, Alban
Cachin, Florent
Chanchou, Marion
author_sort Margail, Charles
collection PubMed
description BACKGROUND: (68) Ga-PSMA PET is the leading prostate cancer imaging technique, but the image quality remains noisy and could be further improved using an artificial intelligence-based denoising algorithm. To address this issue, we analyzed the overall quality of reprocessed images compared to standard reconstructions. We also analyzed the diagnostic performances of the different sequences and the impact of the algorithm on lesion intensity and background measures. METHODS: We retrospectively included 30 patients with biochemical recurrence of prostate cancer who had undergone (68) Ga-PSMA-11 PET-CT. We simulated images produced using only a quarter, half, three-quarters, or all of the acquired data material reprocessed using the SubtlePET® denoising algorithm. Three physicians with different levels of experience blindly analyzed every sequence and then used a 5-level Likert scale to assess the series. The binary criterion of lesion detectability was compared between series. We also compared lesion SUV, background uptake, and diagnostic performances of the series (sensitivity, specificity, accuracy). RESULTS: VPFX-derived series were classified differently but better than standard reconstructions (p < 0.001) using half the data. Q.Clear series were not classified differently using half the signal. Some series were noisy but had no significant effect on lesion detectability (p > 0.05). The SubtlePET® algorithm significantly decreased lesion SUV (p < 0.005) and increased liver background (p < 0.005) and had no substantial effect on the diagnostic performance of each reader. CONCLUSION: We show that the SubtlePET® can be used for (68) Ga-PSMA scans using half the signal with similar image quality to Q.Clear series and superior quality to VPFX series. However, it significantly modifies quantitative measurements and should not be used for comparative examinations if standard algorithm is applied during follow-up.
format Online
Article
Text
id pubmed-10212905
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-102129052023-05-27 Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer Margail, Charles Merlin, Charles Billoux, Tommy Wallaert, Maxence Otman, Hosameldin Sas, Nicolas Molnar, Ioana Guillemin, Florent Boyer, Louis Guy, Laurent Tempier, Marion Levesque, Sophie Revy, Alban Cachin, Florent Chanchou, Marion EJNMMI Res Original Research BACKGROUND: (68) Ga-PSMA PET is the leading prostate cancer imaging technique, but the image quality remains noisy and could be further improved using an artificial intelligence-based denoising algorithm. To address this issue, we analyzed the overall quality of reprocessed images compared to standard reconstructions. We also analyzed the diagnostic performances of the different sequences and the impact of the algorithm on lesion intensity and background measures. METHODS: We retrospectively included 30 patients with biochemical recurrence of prostate cancer who had undergone (68) Ga-PSMA-11 PET-CT. We simulated images produced using only a quarter, half, three-quarters, or all of the acquired data material reprocessed using the SubtlePET® denoising algorithm. Three physicians with different levels of experience blindly analyzed every sequence and then used a 5-level Likert scale to assess the series. The binary criterion of lesion detectability was compared between series. We also compared lesion SUV, background uptake, and diagnostic performances of the series (sensitivity, specificity, accuracy). RESULTS: VPFX-derived series were classified differently but better than standard reconstructions (p < 0.001) using half the data. Q.Clear series were not classified differently using half the signal. Some series were noisy but had no significant effect on lesion detectability (p > 0.05). The SubtlePET® algorithm significantly decreased lesion SUV (p < 0.005) and increased liver background (p < 0.005) and had no substantial effect on the diagnostic performance of each reader. CONCLUSION: We show that the SubtlePET® can be used for (68) Ga-PSMA scans using half the signal with similar image quality to Q.Clear series and superior quality to VPFX series. However, it significantly modifies quantitative measurements and should not be used for comparative examinations if standard algorithm is applied during follow-up. Springer Berlin Heidelberg 2023-05-25 /pmc/articles/PMC10212905/ /pubmed/37231229 http://dx.doi.org/10.1186/s13550-023-00999-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Research
Margail, Charles
Merlin, Charles
Billoux, Tommy
Wallaert, Maxence
Otman, Hosameldin
Sas, Nicolas
Molnar, Ioana
Guillemin, Florent
Boyer, Louis
Guy, Laurent
Tempier, Marion
Levesque, Sophie
Revy, Alban
Cachin, Florent
Chanchou, Marion
Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer
title Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer
title_full Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer
title_fullStr Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer
title_full_unstemmed Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer
title_short Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer
title_sort imaging quality of an artificial intelligence denoising algorithm: validation in (68)ga psma-11 pet for patients with biochemical recurrence of prostate cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212905/
https://www.ncbi.nlm.nih.gov/pubmed/37231229
http://dx.doi.org/10.1186/s13550-023-00999-y
work_keys_str_mv AT margailcharles imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer
AT merlincharles imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer
AT billouxtommy imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer
AT wallaertmaxence imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer
AT otmanhosameldin imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer
AT sasnicolas imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer
AT molnarioana imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer
AT guilleminflorent imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer
AT boyerlouis imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer
AT guylaurent imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer
AT tempiermarion imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer
AT levesquesophie imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer
AT revyalban imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer
AT cachinflorent imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer
AT chanchoumarion imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer